Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Y-mAbs Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of ($0.67) for the year. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the firm posted ($0.18) earnings per share.

Several other equities analysts also recently weighed in on YMAB. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $6.19 on Wednesday. Y-mAbs Therapeutics has a 52-week low of $6.01 and a 52-week high of $20.90. The stock has a fifty day simple moving average of $8.96 and a 200-day simple moving average of $11.82. The company has a market capitalization of $277.25 million, a PE ratio of -11.46 and a beta of 0.69.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $133,000. SG Americas Securities LLC purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth $210,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.